The US wellness industry and investment
English 한국어 The GLP-1 Revolution & Pharmaceutical Leaders The US wellness industry has evolved into a staggering $2.1 trillion market by 2026, transitioning decisively from traditional fitness models to deep metabolic health and personalized medicine. A primary catalyst for this revolution is the exponential growth of GLP-1 weight loss treatments. Pharmaceutical titans such as Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) are at the forefront of this shift. Eli Lilly continues to solidify its market dominance through the success of Mounjaro and Zepbound, alongside its anticipated next-generation oral therapeutics. Concurrently, Novo Nordisk drives innovation with Wegovy and Ozempic, proving pivotal not just in weight reduction, but in mitigating long-term cardiovascular risks. Consumer Wellness & Telehealth Integration In the consumer arena, forward-thinking companies are successfully blending telemedicine with lifestyle m...